Pfizer completes Metsera acquisition in deal worth up to $10 bn / Photo: © AFP/File
-
Mets President David Stearns Expresses Confidence in Marcus Semien's Motivation
-
Florida AG Investigates DSA Politicians Over Suspected Chinese and Cuban Funding
-
UK’s Longest-Running Reggae Night Jam Jah Celebrates 25 Years
-
Bromsgrove Sporting Extend Unbeaten Run to 12 Matches with Victory Over Leiston
-
Olivier Martinez Seeks Increased Child Support from Halle Berry Following Custody Change
-
Russia Orders 100,000 Kometa Modules to Counter Ukrainian Electronic Warfare
-
Polestar Unveils Formula 2030 Concept Car to Signal Future Design Direction
-
Paradise Valley United Methodist Church to Host Fifth Annual Christmas Bazaar
-
Pennsylvania Measles Cases Reach 1,505 as Bucks County Reports New Infection
Pfizer completes Metsera acquisition in deal worth up to $10 bn
US drugmaker Pfizer said Thursday that it has completed its acquisition of biotech firm Metsera, closing a deal worth up to $10 billion after a fierce bidding war.
The approval from Metsera's shareholders opens the door for Pfizer to make inroads into the fast-growing market for weight loss drugs.
Metsera, a US company specializing in obesity treatments, had been the subject of escalating offers from Pfizer and Danish challenger Novo Nordisk, which makes the weight loss drug Wegovy and Ozempic, a diabetes medication with weight loss benefits.
Pfizer said in a statement that its acquisition was successfully completed.
It had offered to acquire Metsera for up to $86.25 per share, making the deal worth around $10 billion.
This involved $65.60 per share in cash, and an additional $20.65 per share linked to the success of its drug pipeline.
"By acquiring Metsera, we are directing our resources toward one of the most impactful and high-growth therapeutic areas and positioning ourselves to define it," said Pfizer chief executive Albert Bourla.
"We look forward to combining Metsera's innovative portfolio with our global development, manufacturing and commercial infrastructure," he added.
The potential sale of Metsera to Novo Nordisk had drawn scrutiny over potential antitrust implications.
E.Burkhard--VB
